An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the fixed dose combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not adequately responding to a 4 week therapy with the free combination of an angiotensin receptor blocker (olmesartan 20 mg) plus amlodipine 10 mg

Trial Profile

An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the fixed dose combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not adequately responding to a 4 week therapy with the free combination of an angiotensin receptor blocker (olmesartan 20 mg) plus amlodipine 10 mg

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Amlodipine/valsartan (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 02 Dec 2008 Actual patient number (256) added as reported by ClinicalTrials.gov.
    • 02 Dec 2008 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
    • 02 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top